Skip to main content

Response Genetics Regains Nasdaq Compliance After Private Placement

NEW YORK (GenomeWeb News) – Response Genetics said on Monday that it has regained compliance with a Nasdaq requirement calling for a minimum $35 million market value of listed securities.

The Los Angeles-based diagnostics firm said that Nasdaq notified it that it regained compliance on Oct. 5 and the delisting matter is now closed.

Nasdaq had notified Response Genetics in July of its non-compliance. Last month, the company raised $8.8 million in a private placement with a "significant" stockholder. Response Genetics later disclosed in a document filed with the US Securities and Exchange Commission that the investors in the placement are the Glaxo Group and Swiftcurrent Partners.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.